-
1.发明公开BROAD SPECTRUM MONOCLONAL ANTIBODY IDENTIFYING HA1 STRUCTURAL DOMAIN OF INFLUENZA VIRUS HEMAGGLUTININ PROTEINS 审中-公开HA1结构域流感病毒HÄMAGGLUTININPROTEINEN作者：抗体鉴定单克隆宽范围
公开(公告)号：EP2982691A1
公开(公告)日：2016-02-10
申请号：EP14778269.2
申请日：2014-04-02
申请人： Xiamen University
发明人： CHEN, Yixin , ZHENG, Qingbing , LI, Rui , SHEN, Chenguang , KE, Shaojun , LUO, Wenxin , CHEN, Honglin , XIA, Ningshao
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/76 , G01N33/56983 , G01N2333/11 , G01N2469/10
摘要： The invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin (HA) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also relates to vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g. influenza), comprising the antibodies according to the invention.
摘要翻译： 本发明涉及的抗体认识到关于流感病毒，细胞系的血凝素（HA）蛋白的HA1结构域的表位用于产生抗体，以及它们的用途。 gemäß到本发明的抗体可以特异性结合于不同HA亚型的HA1结构域和特异性结合H1亚型（包括季节性H1N1和大流行性H1N1 2009）和流感病毒H5亚型的血凝素（HA）蛋白的HA1结构域。 因此，本发明因此涉及疫苗或用于预防和/或治疗H1亚型H5和亚型A型流感病毒和/或由感染（E. G.流感）引起的疾病的感染的药物组合物，包含gemäß到本发明的抗体。
-
公开(公告)号：EP2860188B1
公开(公告)日：2020-10-21
申请号：EP13804161.1
申请日：2013-06-06
发明人： YUAN, Quan , ZHANG, Tianying , LUO, Wenxin , CHEN, Yixin , ZHANG, Jun , XIA, Ningshao
-
公开(公告)号：EP3360896A1
公开(公告)日：2018-08-15
申请号：EP16853117.6
申请日：2016-10-09
发明人： LUO, Wenxin , ZHOU, Bing , ZHANG, Juan , YUAN, Quan , ZHANG, Tianying , ZHANG, Jun , XIA, Ningshao
CPC分类号： A61K39/395 , C07K16/10 , C12N5/10 , C12N15/63
摘要： The invention provides an antibody (in particular, a humanized antibody) against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the same, a method for preparing the same, and a pharmaceutical composition comprising the same. The invention also provides use of the antibody and pharmaceutical composition. The antibody and pharmaceutical composition according to the invention can be used for preventing and/or treating HBV infection or a disease associated with HBV infection (such as Hepatitis B), for neutralizing HBV virulence in a subject (such as human), or for reducing the serum level of HBV DNA and/or HBsAg in a subject.
-
公开(公告)号：EP2154147B1
公开(公告)日：2015-10-07
申请号：EP08748431.7
申请日：2008-04-29
发明人： GU, Ying , LI, Shaowei , WEI, Minxi , XIAN, Yangling , LUO, Wenxin , XIA, Ningshao
IPC分类号： C12N7/02 , C07K14/025 , A61K39/12
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5258 , A61K2039/55505 , A61K2039/55566 , A61K2039/70 , C12N7/00 , C12N2710/20022 , C12N2710/20034
-
公开(公告)号：EP2982691B1
公开(公告)日：2020-05-06
申请号：EP14778269.2
申请日：2014-04-02
申请人： Xiamen University
发明人： CHEN, Yixin , ZHENG, Qingbing , LI, Rui , SHEN, Chenguang , KE, Shaojun , LUO, Wenxin , CHEN, Honglin , XIA, Ningshao
-
6.发明公开POLYPEPTIDES AND ANTIBODIES FOR TREATING HBV INFECTION AND RELATED DISEASES 审中-公开用于治疗HBV感染和相关疾病的多肽和抗体
公开(公告)号：EP3308798A2
公开(公告)日：2018-04-18
申请号：EP17203789.7
申请日：2013-06-06
发明人： YUAN, Quan , ZHANG, Tianying , LUO, Wenxin , CHEN, Yixin , ZHANG, Jun , XIA, Ningshao
IPC分类号： A61K39/12
摘要： The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositons for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.
摘要翻译： 本发明涉及用于治疗乙型肝炎病毒感染的表位肽（或其突变体），包含此类表位肽（或其突变体）和载体蛋白的重组蛋白，以及此类表位肽（或其突变体）和重组蛋白的用途。 本发明还涉及抗此类表位肽的抗体，产生所述抗体的细胞系及其用途。 此外，本发明涉及用于治疗或缓解与乙型肝炎病毒感染相关的一种或多种症状的疫苗或药物组合物，其分别包含根据本发明的重组蛋白或抗体。
-
7.发明公开FUSION PROTEIN COMPRISING DIPHTHERIA TOXIN NON-TOXIC MUTANT CRM197 OR FRAGMENT THEREOF 有权使用无毒的白喉毒素突变体CRM197或其片段融合蛋白
公开(公告)号：EP2716661A1
公开(公告)日：2014-04-09
申请号：EP12793630.0
申请日：2012-06-01
发明人： LI, Shaowei , SONG, Cuiling , YANG, Chunyan , GU, Ying , LUO, Wenxin , XIA, Ningshao
CPC分类号： A61K39/39 , A61K38/00 , A61K39/05 , A61K39/12 , A61K39/29 , A61K2039/55505 , A61K2039/55516 , A61K2039/55544 , A61K2039/6037 , C07K14/005 , C07K14/34 , C07K2319/03 , C07K2319/55 , C07K2319/74 , C12N7/00 , C12N9/1048 , C12N15/62 , C12N2760/16122 , C12N2760/16134 , C12N2770/28122 , C12N2770/28134
摘要： Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
-
公开(公告)号：EP3981786A1
公开(公告)日：2022-04-13
申请号：EP20809871.5
申请日：2020-05-22
发明人： LUO, Wenxin , WEN, Can , XIANG, Xinchu , TANG, Jixian , WU, Yangtao , ZHANG, Tianying , YUAN, Quan , XIA, Ningshao
摘要： Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and/or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and/or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.
-
公开(公告)号：EP3308798B1
公开(公告)日：2020-09-09
申请号：EP17203789.7
申请日：2013-06-06
发明人： YUAN, Quan , ZHANG, Tianying , LUO, Wenxin , CHEN, Yixin , ZHANG, Jun , XIA, Ningshao
IPC分类号： A61K39/12
-
公开(公告)号：EP3308798A3
公开(公告)日：2018-05-30
申请号：EP17203789.7
申请日：2013-06-06
发明人： YUAN, Quan , ZHANG, Tianying , LUO, Wenxin , CHEN, Yixin , ZHANG, Jun , XIA, Ningshao
IPC分类号： A61K39/12
摘要： The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositons for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.019 秒)
